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Introduction
Multiple prospective randomized trials, now with long-term follow-up, have demonstrated 
that survival after breast conserving surgery (BCS) and whole breast radiotherapy is 
equivalent to mastectomy.1 Over time, rates of local recurrence after BCS have decreased 
and are now very similar to those seen after mastectomy.2, 3 In spite of this, a recent increase 
in rates of mastectomy in the United States has been observed after years of steady decline.4 
In particular, women increasingly opt for bilateral instead of unilateral mastectomies even in 
the absence of a genetic predisposition or oncologic risk factor supporting the use of 
contralateral prophylactic mastectomy (CPM).5–7 This trend is particularly concerning as 
rates of contralateral breast cancer have also decreased due to the widespread use of 
adjuvant systemic therapy for early stage breast cancer, and there is no evidence that 
bilateral mastectomies with CPM prolong survival for women with sporadic breast cancer.8 
Greater use of mastectomy, and particularly CPM, have been associated with younger age at 
diagnosis, greater educational attainment and socioeconomic status, race, higher histologic 
grade and in situ cancer (stage 0).4, 6, 9 While single-institution studies have shown an 
association between breast reconstruction and bilateral mastectomies with CPM, little is 
known about this relationship in larger and more representative patient samples.7
The Women’s Cancer and Health Rights Act (WCHRA) was enacted in 1998 to secure 
insurance coverage for breast reconstruction following mastectomy.10 Since the introduction 
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of this legislation, rates of immediate breast reconstruction have increased gradually to 
approximately 38% of mastectomies.11 Greater access of immediate breast reconstruction 
may be an important unmeasured factor in women’s choice of surgical treatment for ESBC. 
For example, women who choose bilateral mastectomy have reconstruction rates 
approximately twice as high as women who choose unilateral mastectomy.11 The aim of the 
current study was to examine trends in the surgical management of ESBC while 
simultaneously assessing the role of breast reconstruction. We hypothesized that greater 
access to breast reconstruction is associated with the use of mastectomy for ESBC.
Methods
Data Source and Study Cohort
The primary data source was the National Cancer Data Base (NCDB), a joint initiative of 
the Commission on Cancer (CoC), the American College of Surgeons (ACoS) and the 
American Cancer Society. The NCDB is a nationwide oncology outcomes database for more 
than 1,500 Commission-accredited cancer programs. It includes information about patient 
and disease characteristics, treatment and outcomes for about 70% of all newly diagnosed 
cancers in the US and Puerto Rico.12 The study was approved by the CoC review board. The 
Commission on Cancer of the ACS does not require IRB approval for the current study since 
no patient identifiers are collected as part of the database.
The study cohort included women diagnosed with unilateral ESBC (stage 0, I or II of the 
American Joint Commission on Cancer (AJCC) staging criteria, 7th edition) from 1998 to 
2011.13 Patients with synchronous bilateral cancers were excluded.
Outcomes and Predictors
The primary outcome was type of surgery, based on NCDB site-specific codes for breast 
conserving surgery (BCS), unilateral (UM), and bilateral procedures with contralateral 
prophylactic mastectomy (CPM). CPM was defined as bilateral mastectomy performed for 
unilateral breast cancer. Patients with unspecified or unknown type of surgery were 
excluded from analysis. The predictor of interest was the availability of breast 
reconstruction, based on annual rates of immediate, post-mastectomy breast reconstruction 
as recorded by the NCDB. All patients treated in a calendar year were assumed to have the 
same access to reconstruction.
Sociodemographic covariates and health characteristics included age at diagnosis, race, 
Charlson comorbidity score, median income and percent of non-high school graduates in the 
zip code of residence, type of health insurance, urban vs. rural residence, and facility 
geographic location. Disease characteristics included histology (lobular vs. ductal), tumor 
size, grade, invasion and the number of positive lymph nodes.
Statistical Analysis
Rates of each surgical procedure per 1,000 cases of ESBC were estimated for each year. 
Trends over time were analyzed using the Cochrane-Armitage test and Poisson regression. 
For the Poisson model, the dependent variable was the procedure rate, and the single 
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independent variable was calendar year, with an observation for each year in the study 
period. The incidence rate ratio (IRR) estimated for year describes the trend in procedure 
rate over time, with values > 1.0 implying an increase and values < 1.0 suggesting a 
decrease. The influence of breast reconstruction rates on surgical treatment was estimated 
using a multinomial logistic regression model, controlling for sociodemographic and disease 
characteristics. In this model we estimated the impact of the predictor and covariates on the 
relative risk of CPM and the relative risk of UM, each compared with BCS. Variables were 
considered significant independent predictors of the outcome if p < 0.05.
In order to estimate the proportion of variability in CPM and UM use associated with each 
predictor, two separate multivariable logistic regression models for two outcomes were 
estimated: CPM (versus BCS) and UM (versus BCS). Changes in the pseudo-R2 for each 
model as each predictor was included and excluded were evaluated.14 All statistical analyses 
were performed using Stata 11.0 (Stata Corp., College Station, Texas).
Results
A total of 1,856,702 patients diagnosed with ESBC from 1998 to 2011were identified in the 
NCDB. The mean age at diagnosis was 60 years and 76% of patients were Caucasian (Table 
1). Over 90% of patients had a Charlson comorbidity score of 0. More than half of the 
cohort (56%) had private health insurance, and only 2% were uninsured. Invasive cancer 
was present in 85% of cases, and of these, 60% of patients had a tumors less than 2 cm in 
size (T1). Only 14% of tumors were of lobular histology, and 79.5% did not have nodal 
involvement.
Figure 1 and Table 4 show rates of BCS and mastectomy per 1,000 cases of ESBC from 
1998–2011. Mastectomy rates decreased from 459 per 1,000 in 1998 to a nadir of 361 per 
1,000 in 2005 (p < 0.01 for trend). Thereafter, mastectomy rates steadily increased to 403 
per 1,000 in 2011 (p < 0.01).
Figure 2 is a graphical representation of surgical trends for ESBC stratified by mastectomy 
type. From 1998 to 2005 BCS use increased from 540 to 639 per 1,000 ESBC (IRR 1.02, p 
< 0.01) while the rates of UM decreased from 437 to 306 per 1,000 ESBC (IRR 0.94, p < 
0.01) (Figure 1). After 2005, the rates of BCS declined by 2% per year from 637 to 597 per 
1,000 ESBC (IRR 0.98 p < 0.01), but without a significant corresponding increase in UM 
(IRR 0.99, p=NS). The rate of CPM increased significantly throughout the entire study 
period (IRR 1.13, p < 0.01). From 2005 to 2011, the rate of BCS decreased by 42 per 1,000 
cases while there was a simultaneous increase in the rate of CPM of 64 per 1,000 ESBC 
(from 54 to 118 per 1,000 ESBC). This corresponds with a decrease in rates of UM by 22 
per 1,000 cases during that time (from 306 to 284 per 1,000 ESBC).
Reconstruction use varied by year and by type of surgery (Table 5). Women who had CPM 
were more than twice as likely to have reconstruction as their peers who had UM. 
Immediate reconstruction rates after UM increased from 10% in 1998 to 27% in 2011, while 
reconstruction after CPM increased from 37% to 57%.
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Independent predictors of the use of CPM compared to BCS were identified using a 
multinomial logistic regression model (Table 2). After adjustment for other factors, 
multivariable analysis demonstrated a significant association between the decision to pursue 
a CPM and breast reconstruction rates (RRR 1.07, 95% CI 1.05-1.07, p < 0.01), Young age, 
race other than African American, lower education level, rural area of residency, facility 
location, presence of comorbidities, large tumor size (> 5 cm), positive lymph nodes, DCIS, 
higher grade, and lobular histology were also significantly associated with a women’s 
decision to undergo CPM. The relative contribution of each factor to the likelihood of CPM 
is shown in Table 3. The three factors most associated with CPM were young age (32.2%), 
breast reconstruction (28.6%), and stage 0 (DCIS) (4.6%).
Independent predictors for the use of UM compared to BCS were also examined in the 
multinomial logistic regression model (Table 2). Factors significantly associated with UM 
were older age, all races compared to African Americans, comorbidities, lower income, 
lower education status, rural area of residency, facility location, Medicaid, Medicare and 
other governmental insurances compared to private insurance, large tumors (> 5cm), 
positive lymph nodes, higher tumor grade, stage 0 (DCIS), and lobular histology. Breast 
reconstruction was negatively associated with UM (RRR 0.98, p < 0.01). The relative 
contribution of each factor to the likelihood to undergo UM is shown in Table 6. The most 
relevant factors were tumor size (43.4%), presence of DCIS (24.2%) and positive lymph 
nodes (13.5%).
Discussion
Most women with ESBC can be treated safely with BCS with the added benefit of 
preserving the native breast. However, surgical treatment for ESBC is a “preference-
sensitive” decision that should be made together by the patient and her breast surgeon 
considering individual clinical factors in conjunction with the patient’s values and 
preferences. The current study confirms, in a large, diverse patient sample, that after several 
years of decreasing use, rates of mastectomy for ESBC have risen since 2005. The trend of 
increased mastectomy rates identified in the current study is in agreement with a recent 
report from the SEER database.4 In that study, the choice for mastectomy was associated 
with a variety of sociodemographic and oncologic variables; however, there was no 
evaluation of mastectomy type (CPM versus UM) or breast reconstruction. The current 
report is novel in that it demonstrates a decrease of BCS, but without a corresponding 
increase in UM. Instead, patients may be deciding between BCS and removal of both breasts 
(CPM) when diagnosed with ESBC (Figure 2).
Why more women are choosing an aggressive surgical treatment for ESBC when less 
invasive alternatives are available is unclear.25 Most bilateral mastectomies with CPM are 
performed in patients who are at low-risk of developing contralateral cancer.7 Although the 
10-year risk of contralateral cancer is approximately 5%, newly diagnosed patients tend to 
overestimate their level of risk.15, 16 Other reasons patients cite for choosing CPM include 
achieving “peace of mind”, avoidance of ongoing surveillance and diagnostic procedures, 
and desire for breast symmetry following reconstruction.17, 18 While in the past access to 
breast reconstruction was limited, breast reconstruction is now more available with coverage 
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mandated through federal and state legislation. Furthermore, improvements in both 
mastectomy (e.g. skin sparing and nipple sparing) and reconstructive (e.g. silicone implant 
safety and shape) techniques may make CPM an increasingly attractive option for women. 
Other reasons that could partially explain the decision of undergo CPM over BCS are 
avoidance of radiotherapy and chance of recurrence.
While a variety of sociodemographics and oncologic factors impact decision-making for the 
surgical treatment of ESBC, breast reconstruction needs to be considered. In this study, 
breast reconstruction rates were the second most important factor associated with 
undergoing CPM compared to BCS (explaining 28% of the variability). Only patient age 
was more strongly associated with the use of bilateral mastectomies with CPM. 
Interestingly, breast reconstruction was negatively associated with the decision for UM 
compared to BCS. The choice for UM for ESBC is better explained by oncologic factors 
(tumor size, DCIS, and positive lymph nodes). The strength of the relationship between 
mastectomy type and breast reconstruction is evidenced by the reconstructive rates for CPM, 
which are more than double those for UM. Breast reconstruction appears to substantially 
influence patient choice of bilateral mastectomy for ESBC. In a study of 206 patients who 
underwent CPM, 59% of them indicated that the availability of breast reconstruction was an 
influencing factor in the decision.19 A population-based survey of 1,178 women from two 
major metropolitan areas, showed that patients who discussed breast reconstruction with 
their general surgeon were 2 times more likely to consider mastectomy and 4 times more 
likely to receive a mastectomy.20 Greenberg et al, using a patient sample from the National 
Comprehensive Cancer Network found that greater numbers of plastic surgeons and a 
shorter waiting time to mastectomy with reconstruction were significantly associated with 
the use of mastectomy rather than BCS, although they did not analyze UM and CPM 
separately.14 Along with cancer fear, “Desire to have both breasts look the same after 
surgery” (57%) and “Desire to make breasts look better” (27%) are considerations for CPM 
cited by women when asked about important reasons for undergoing this procedure.17, 21
In breast cancer surgery, the quality of the decisions can be estimated by the extent to which 
patients are informed, involved in decision-making, and undergo treatments that reflect their 
values.22 Greater patient involvement has been associated with increased likelihood of 
mastectomy; however, greater involvement is separate from health literacy.23 
Approximately 35–40% of ESBC patients have adequate knowledge about survival or 
recurrence rates following BCS and mastectomy.22 Furthermore, the risk of developing 
contralateral cancer is overestimated by women.16 Patients may also have unrealistic 
expectations about the reconstructive benefits of CPM. A multicenter study showed that 21–
33% of patients who underwent CPM felt that the number of surgical procedures, cosmetic 
results, complications and recovery from reconstructive surgery were worse than expected.21 
Patients should be aware of the increased complication rates following bilateral 
mastectomies, 7.6% compared to 4.2% in unilateral procedures.24 Improved preoperative 
education is needed to ensure high quality decisions are made while simultaneously setting 
realistic expectations.
It seems counterintuitive that in an era of minimally invasive surgery, many women with 
ESBC are choosing more extensive treatment. The current patient-centered healthcare model 
Albornoz et al. Page 5













has empowered patients to become active participants in their care decisions undergoing 
services based on individual needs/preferences.25 A possible explanation for the evolution in 
women’s surgical choice from BCS to bilateral mastectomy is that both treatments share the 
property of theoretical symmetry. Although not all patients who have BCS or bilateral 
mastectomy end up with symmetry, patients who are deciding about surgery likely consider 
these options as maximizing symmetry (and UM as not preserving symmetry). Another 
possible explanation for re-framing of the surgical choice may be a form of decision 
momentum.26 Once the patient knows she will not have BCS, either by choice or medical 
necessity, she may begin to put less value on the importance of preserving her contralateral 
breast, consciously or unconsciously. People are known to respond to adverse circumstances 
or loss of choice by reducing their cognitive dissonance through adaptation or even 
preference reversal.27–30
The current study has limitations. The NCDB is not a population-based registry, although 
the large numbers of ESBC patients included in the current analysis may confer 
generalizability. The trends reported herein are also concordant with findings using the 
SEER database, further supporting their validity.4 Other limitations include a lack of 
information on previous attempts at BCS, incidence of multicentricity, BRCA mutation 
status, high familiar/genetic risk or preoperative MRI use, all factors which influence the 
decision for mastectomy. The information presented here demonstrates an association 
between breast reconstruction rates and surgical treatment for ESBC, but does not imply 
causality. Further insight about the role of breast reconstruction on the decision-making 
process for CPM needs to be obtained through qualitative interviews with patients. Another 
limitation is that NCDB has no information on delayed reconstruction. The association 
between reconstruction and CPM may be stronger if delayed reconstructions were included.
In conclusion, since 2005 an increasing proportion of patients with ESBC are choosing 
mastectomy for their surgical treatment. The observed increase in mastectomy rates is 
attributable to a shift towards bilateral mastectomy with CPM, not UM. While a variety of 
oncologic factors influence decision-making, wider breast reconstruction access and 
acceptance may facilitate the option for more radical surgery. Evolution of the surgical 
treatment for ESBC has important implications for patient care, the design of decision 
support tools, and health care policy.
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Surgical treatment for early-stage breast cancer by year
*Dashed line represents the nadir of mastectomy rates
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Trends in surgery for early-stage breast cancer, 1998–2011
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Table 1
Characteristics of the cohort
n %
























Other public 13,766 0.7
Uninsured 33,675 1.8









T0 (DCIS) 286,481 15.4
T1 (<2 cm) 1,120,490 60.4
T2 (2–4.9 cm) 429,379 23.1
T3 (>5 cm) 20,352 1.1
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n %
Positive lymph nodes
N0 (None) 1,475,372 79.5
N1 (1–3) 381,330 20.5
Tumor grade
Well differentiated 380,124 20.5
Moderately differentiated 699,526 37.7
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Table 3
Variability in contralateral prophylactic mastectomy use (compared to BCS) explained by patient, disease and 
area characteristics
Characteristic % of variation explained
Young age 32
Breast reconstruction 29





Percent of variation explained by each characteristic based on change in logistic regression pseudo-R2, with and without each characteristic. Only 
variables that changed the pseudo R2 by ≥2% are shown here. The full model included all characteristics shown in Table 3, and had a pseudo R2 of 
0.1274, c-statistic 0.75, n=1,149,395.













Albornoz et al. Page 17
Table 4
Annual rates of mastectomy* compared to breast conserving surgery (BCS) for the treatment of ESBC.
Rates per 1,000 ESBC
Year ESBC BCS Mastectomy*
1998 122,178 540.8 459.2
1999 127,460 557.7 442.3
2000 129,240 574.1 425.9
2001 131,900 580.3 419.7
2002 132,758 598.6 401.4
2003 124,646 630.5 369.5
2004 122,815 635.3 364.7
2005 125,789 639.5 360.5
2006 131,545 637.4 362.6
2007 136,021 619.7 380.3
2008 141,313 604.8 395.2
2009 146,468 593.0 407.0
2010 140,553 587.3 412.7
2011 144,016 597.1 402.9
Total 1,856,702
*
Includes both UM and CPM
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Table 5














1998 53,411 10.3 2,690 37.1
1999 52,870 13.1 3,510 44.0
2000 50,874 14.2 4,164 45.2
2001 50,385 14.8 4,969 44.6
2002 47,734 14.5 5,556 43.8
2003 40,357 14.9 5,704 42.8
2004 38,724 15.6 6,069 45.4
2005 38,483 16.6 6,862 46.8
2006 39,419 17.5 8,274 48.8
2007 40,910 19.8 10,822 50.5
2008 42,601 21.7 13,241 51.8
2009 44,521 25.0 15,088 53.1
2010 42,215 26.1 15,787 55.5
2011 40,928 27.4 17,090 56.7
UM: Unilateral mastectomy, CPM: contralateral prophylactic mastectomy
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Table 6




Stage 0 (DCIS) 24
Positive lymph nodes 14
Breast reconstruction rates 5
Health insurance 3
Comorbidities 2
Percent of variation explained by each characteristic based on change in logistic regression pseudo-R2, with and without each characteristic. Only 
variables that changed the pseudo R2 by ≥2% are shown here. The full model included all characteristics shown in Table 3, and had a pseudo R2 of 
0.0495, c-statistic 0.64, n= 1,651,924
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